Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 901–1,000 of 1,021
Wang, J., Mikse, O. R., Liao, R. G., Li, Y. Y., Tan, L., Janne, P. A., Gray, N. S., Wong, K., & Hammerman, P. S. (2014) · Oncogene · doi:10.1038/onc.2014.161 · Cited by 77
The Impact of miRNA-Based Molecular Diagnostics and Treatment of NRF2-Stabilized Tumors
Yamamoto, S., Inoue, J., Kawano, T., Kozaki, K., Omura, K., & Inazawa, J. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0246-t · Cited by 76
KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer
Dai, B., Yoo, S., Bartholomeusz, G. A., Graham, R. A., Majidi, M., Yan, S., Meng, J., Ji, L., Coombes, K. R., Minna, J. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0712 · Cited by 74
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
The Cancer Genome Atlas Research Network: A Sight to Behold
Giordano, T. J. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9345-4 · Cited by 72
Molecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 99
Tran, T. N., Selinger, C. I., Kohonen‐Corish, M. R. J., McCaughan, B. C., Kennedy, C. W., O'Toole, S. A., & Cooper, W. A. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.015 · Cited by 71
Chen, M., Liu, X., Du, J., Wang, X., & Xia, L. (2016) · Oncotarget · doi:10.18632/oncotarget.13346 · Cited by 76
Nagahashi, M., Wakai, T., Shimada, Y., Ichikawa, H., Kameyama, H., Kobayashi, T., Sakata, J., Yagi, R., Sato, N., Kitagawa, Y., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0387-8 · Cited by 81
The role of Hippo‐YAP signaling in squamous cell carcinomas
Maehama, T., Nishio, M., Otani, J., Mak, T. W., & Suzuki, A. (2020) · Cancer Science · doi:10.1111/cas.14725 · Cited by 81
Tan, X., Lu, T., Li, L., Xu, J., Xie, S., Ji, L., Fu, J., Liu, Q., Shen, S., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24898-9 · Cited by 72
The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
Ferguson, B. D., Liu, R., Rolle, C. E., Tan, Y. C., Krasnoperov, V. G., Kanteti, R., Tretiakova, M., Cervantes, G. M., Hasina, R., Hseu, R. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067668 · Cited by 71
Epigenetic and transcriptional determinants of the human breast
Gascard, P., Bilenky, M., Sigaroudinia, M., Zhao, J., Li, L., Carles, A., Delaney, A., Tam, A., Kamoh, B., Cho, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7351 · Cited by 70
Martínez, V. D., Vucic, E. A., Thu, K. L., Pikor, L. A., Lam, S. C., & Lam, W. L. (2014) · Head & Neck · doi:10.1002/hed.23663 · Cited by 76
Lineage factors and differentiation states in lung cancer progression
Cheung, W. K. C., & Nguyen, D. X. (2015) · Oncogene · doi:10.1038/onc.2015.85 · Cited by 80
Dysregulation of ubiquitin ligases in cancer
Qi, J., & Ronai, Z. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.09.001 · Cited by 74
Iranmanesh, S. M., & Guo, N. L. (2014) · Cancer Informatics · doi:10.4137/cin.s14055 · Cited by 69
Arnedos, M., Soria, J., André, F., & Tursz, T. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.002 · Cited by 76
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Van Allen, E. M., Golay, H. G., Liu, Y., Koyama, S., Wong, K., Taylor-Weiner, A., Giannakis, M., Harden, M., Rojas-Rudilla, V., Chevalier, A., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0024 · Cited by 69
Wang, E., Zou, J., Zaman, N., Beitel, L. K., Trifiro, M. A., & Paliouras, M. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.001 · Cited by 73
Qin, Y., Wu, C. W., Taylor, W. R., Sawas, T., Burger, K. N., Mahoney, D. W., Sun, Z., Yab, T. C., Lidgard, G. P., Allawi, H. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0740 · Cited by 75
Farjah, F., Lou, F., Sima, C. S., Rusch, V. W., & Rizk, N. P. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182992421 · Cited by 69
Using Aptamers for Cancer Biomarker Discovery
Chang, Y. M., Donovan, M. J., & Tan, W. (2013) · Journal of Nucleic Acids · doi:10.1155/2013/817350 · Cited by 76
Innovative Clinical Trials: The LUNG‐MAP Study
Steuer, C., Papadimitrakopoulou, V., Herbst, R. S., Redman, M. W., Hirsch, F., Mack, P. C., Ramalingam, S., & Gandara, D. R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.88 · Cited by 72
Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue
Mayrhofer, M., DiLorenzo, S., & Isaksson, A. (2013) · Genome biology · doi:10.1186/gb-2013-14-3-r24 · Cited by 78
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 83
Concha‐Benavente, F., Srivastava, R. M., Ferrone, S., & Ferris, R. L. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.008 · Cited by 75
Zhao, Y., Liu, Q., Acharya, P., Stengel, K. R., Sheng, Q., Zhou, X., Kwak, H., Fischer, M. A., Bradner, J. E., Strickland, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.032 · Cited by 69
Wood, W. A., Krishnamurthy, J., Mitin, N., Torrice, C., Parker, J. S., Snavely, A. C., Shea, T. C., Serody, J. S., & Sharpless, N. E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.029 · Cited by 69
9 H -Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
Picaud, S., Strocchia, M., Terracciano, S., Lauro, G., Méndez, J., Daniels, D. L., Riccio, R., Bifulco, G., Bruno, I., & Filippakopoulos, P. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501893k · Cited by 70
Yang, Z., Xu, J., Li, L., Li, R., Wang, Y., Tian, Y., Guo, W., Wang, Z., Tan, F., Ying, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18702-3 · Cited by 74
EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
Ando, T., Arang, N., Wang, Z., Costea, D. E., Feng, X., Goto, Y., Izumi, H., Gilardi, M., Ando, K., & Gutkind, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02744-4 · Cited by 74
Cancer biology deciphered by single-cell transcriptomic sequencing
Li, Y., Jin, J., & Bai, F. (2021) · Protein & Cell · doi:10.1007/s13238-021-00868-1 · Cited by 88
Culletta, G., Buttari, B., Arese, M., Brogi, S., Almerico, A. M., Saso, L., & Tutone, M. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116355 · Cited by 81
Regulation of Keap1-Nrf2 signaling in health and diseases
Xiao, J.-L., Liu, H.-Y., Sun, C., & Tang, C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09771-4 · Cited by 78
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?
Zhao, X., McCutcheon, J. N., Kallakury, B., Chahine, J. J., Pratt, D. W., Raffeld, M. A., Chen, Y., Wang, C., & Giaccone, G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.010 · Cited by 75
Cruickshanks, H. A., Vafadar-Isfahani, N., Dunican, D. S., Lee, A., Sproul, D., Lund, J. N., Meehan, R. R., & Tufarelli, C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt438 · Cited by 67
Goto, T., Hirotsu, Y., Mochizuki, H., Nakagomi, T., Shikata, D., Yokoyama, Y., Oyama, T., Amemiya, K., Okimoto, K., & Omata, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16096 · Cited by 69
Zhou, G. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0180 · Cited by 77
Zhu, C., Ho, Y.-J., Salomao, M. A., Dapito, D. H., Bartolomé, A., Schwabe, R. F., Lee, J., Lowe, S. W., & Pajvani, U. B. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.032 · Cited by 76
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma
Farhangdoost, N., Horth, C., Hu, B., Bareke, E., Chen, X., Li, Y., Coradin, M., Garcia, B. A., Lü, C., & Majewski, J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108769 · Cited by 70
Hatano, Y., Ideta, T., Hirata, A., Hatano, K., Tomita, H., Okada, H., Shimizu, M., Tanaka, T., & Hara, A. (2021) · Cancers · doi:10.3390/cancers13112625 · Cited by 77
Chapel, D. B., Hornick, J. L., Barlow, J. S., Bueno, R., & Sholl, L. M. (2022) · Modern Pathology · doi:10.1038/s41379-022-01081-z · Cited by 81
Kotsakis, A. P., Papadimitraki, E., Vetsika, E., Aggouraki, D., Dermitzaki, E. K., Hatzidaki, D., Kentepozidis, N. K., Mavroudis, D., & Georgoulias, V. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.018 · Cited by 74
Subbiah, V., Berry, J., Roxas, M., Guha‐Thakurta, N., Subbiah, I. M., Ali, S. M., McMahon, C., Miller, V. A., Cascone, T., Pai, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.004 · Cited by 71
The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment
Yaffe, M. B. (2013) · Science Signaling · doi:10.1126/scisignal.2003684 · Cited by 67
Wang, J., Qian, J., Hoeksema, M. D., Zou, Y., Espinosa, A. V., Rahman, S. M. J., Zhang, B., & Massion, P. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0594 · Cited by 77
Marien, E., Meister, M. A., Muley, T., del Pulgar, T. G., Derua, R., Spraggins, J. M., de Plas, R. V., Vanderhoydonc, F., Machiels, J., Binda, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7179 · Cited by 68
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture
Chen, S., Giannakou, A., Wyman, S., Gruzas, J., Golas, J., Zhong, W., Loreth, C., Sridharan, L., Yamin, T.-T., Damelin, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803718115 · Cited by 67
Xie, Z., Liu, L., Lin, X., Xie, X., Gu, Y., Liu, M., Zhang, J., Ouyang, M., Lizaso, A., Zhang, H., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0391-9 · Cited by 68
Non-coding RNA profile in lung cancer
Ghafouri‐Fard, S., Shoorei, H., Branicki, W., & Taheri, M. N. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104411 · Cited by 68
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 75
STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
D’Amico, S., Shi, J., Martin, B. L., Crawford, H. C., Petrenko, O., & Reich, N. C. (2018) · Genes & Development · doi:10.1101/gad.311852.118 · Cited by 68
Abraham, C. G., Ludwig, M. P., Andrysík, Z., Pandey, A., Joshi, M., Galbraith, M. D., Sullivan, K. D., & Espinosa, J. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.058 · Cited by 69
New Treatment Options in Advanced Squamous Cell Lung Cancer
Paik, P. K., Pillai, R. N., Lathan, C. S., Alarcon, S. V., & Papadimitrakopoulou, V. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237829 · Cited by 78
Lin, Q. D., Zhang, H., Ding, H., Qian, J., Lizaso, A., Lin, J., Han‐Zhang, H., Xiang, J., Li, Y., & Zhu, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2036-7 · Cited by 70
Recent advances in preclinical models for lung squamous cell carcinoma
Pan, Y., Han, H., Labbe, K. E., Zhang, H., & Wong, K. (2021) · Oncogene · doi:10.1038/s41388-021-01723-7 · Cited by 74
Using DNA sequencing data to quantify T cell fraction and therapy response
Bentham, R. B., Litchfield, K., Watkins, T. B. K., Lim, E. L., Rosenthal, R., Martínez‐Ruiz, C., Hiley, C. T., Bakir, M. A., Salgado, R., Moore, D. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03894-5 · Cited by 68
Cell Painting predicts impact of lung cancer variants
Caicedo, J. C., Arevalo, J., Piccioni, F., Bray, M.-A., Hartland, C. L., Wu, X., Brooks, A. N., Berger, A. H., Boehm, J. S., Carpenter, A. E., et al. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-11-0538 · Cited by 62
Loriot, A. E., Tongelen, A. V., Blanco, J., Klaessens, S., Cannuyer, J., van Baren, N., Decottignies, A., & Smet, C. D. (2014) · Epigenetics · doi:10.4161/epi.29628 · Cited by 71
Optimal Drug Prediction From Personal Genomics Profiles
Sheng, J., Li, F., & Wong, S. T. C. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2412522 · Cited by 70
PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data
Bahceci, I., Doğrusöz, U., La, K., Babur, Ö., Gao, J., & Schultz, N. D. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx149 · Cited by 66
p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2
Cloer, E. W., Siesser, P. F., Cousins, E. M., Goldfarb, D., Mowrey, D. D., Harrison, J. S., Weir, S., Dokholyan, N. V., & Major, M. B. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00644-17 · Cited by 70
Kashima, J., Kitadai, R., & Okuma, Y. (2019) · Cancers · doi:10.3390/cancers11050599 · Cited by 79
Berge, E. M., & Doebele, R. C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.006 · Cited by 71
Song, J., Wang, W., Wang, Y., Qin, Y., Wang, Y., Zhou, J., Wang, X., Zhang, Y., & Wang, Q. (2019) · BMC Cancer · doi:10.1186/s12885-019-5885-9 · Cited by 70
Kreimer, A. R., Chaturvedi, A. K., Alemany, L., Anantharaman, D., Bray, F., Carrington, M. N., Doorbar, J., DʼSouza, G., Fakhry, C., Ferris, R. L., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104736 · Cited by 68
MacLeod, A. K., Acosta-Jimenez, L., Coates, P. J., McMahon, M., Carey, F. A., Honda, T., Henderson, C. J., & Wolf, C. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.363 · Cited by 64
FGFR as potential target in the treatment of squamous non small cell lung cancer
Tiseo, M., Gelsomino, F., Alfieri, R. R., Cavazzoni, A., Bozzetti, C., Giorgi, A. D., Petronini, P. G., & Ardizzoni, A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.011 · Cited by 71
Personalized Therapy for Lung Cancer
Moreira, A. L., & Eng, J. (2014) · CHEST Journal · doi:10.1378/chest.14-0713 · Cited by 71
Emerging roles of Nrf2 signal in non-small cell lung cancer
Tian, Y., Liu, Q., He, X., Yuan, X., Chen, Y., Chu, Q., & Wu, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0246-5 · Cited by 66
Carbone, M., Shimizu, D., Napolitano, A., Tanji, M., Pass, H. I., Yang, H., & Pastorino, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10653 · Cited by 64
Wu, S.-G., Chang, Y.-L., Yu, C.-J., Yang, P.-C., & Shih, J.-Y. (2016) · Scientific Reports · doi:10.1038/srep35249 · Cited by 65
Predicting cancer type from tumour DNA signatures
Soh, K. P., Szczurek, E., Sakoparnig, T., & Beerenwinkel, N. (2017) · Genome Medicine · doi:10.1186/s13073-017-0493-2 · Cited by 69
Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis
Bohnenberger, H., Kaderali, L., Ströbel, P., Yepes, D., Plessmann, U., Dharia, N. V., Yao, S., Heydt, C., Merkelbach‐Bruse, S., Emmert, A., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708428 · Cited by 69
Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells
Prieto‐Garcia, C., Hartmann, O., Reissland, M., Braun, F., Fischer, T., Walz, S., Schülein‐Völk, C., Eilers, U., Ade, C. P., Calzado, M. A., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911101 · Cited by 67
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes
An, Ö., Pendino, V., D’Antonio, M., Ratti, E., Gentilini, M., & Ciccarelli, F. D. (2014) · Database · doi:10.1093/database/bau015 · Cited by 68
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park, S., Shim, J., Lee, B., Cho, I., Park, W., Kim, Y., Lee, S., Choi, Y., Han, J., Ahn, J. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.024 · Cited by 66
Fusion Genes and RNAs in Cancer Development
Taniue, K., & Akimitsu, N. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010010 · Cited by 81
Guan, L., Nambiar, D. K., Cao, H., Viswanathan, V., Kwok, S., Hui, A. B., Hou, Y., Hildebrand, R., von Eyben, R., Holmes, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1903 · Cited by 69
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
Zhang, Z., Ramnath, N., & Nagrath, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00209 · Cited by 73
Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Satoh, Y., Ishii, N., & Aoki, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0927-t · Cited by 69
Patterns of Chromosomal Aberrations in Solid Tumors
Grade, M., Difilippantonio, M. J., & Camps, J. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_6 · Cited by 70
Stewart, R. L., Piecoro, D. W., Wang, C., Weiss, H. L., Gal, T. S., Durbin, E. B., O’Connor, W. N., Chen, M., & O’Connor, K. L. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.04.003 · Cited by 64
Langer, C. J., Obasaju, C. K., Bunn, P. A., Bonomi, P., Gandara, D. R., Hirsch, F. R., Kim, E. S., Natale, R. B., Novello, S., Paz-Ares, L. G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.138 · Cited by 62
Nagaraj, A. S., Lahtela, J., Hemmes, A., Pellinen, T., Blom, S., Devlin, J. R., Salmenkivi, K., Kallioniemi, O., Mäyränpää, M. I., Närhi, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.059 · Cited by 64
Deng, Y., Luo, S., Deng, C., Luo, T., Yin, W., Zhang, H., Zhang, Y., Zhang, X., Lan, Y., Ping, Y., et al. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx109 · Cited by 68
Kim, E. K., Kim, K., Lee, C. Y., Kim, S., Chang, S. H., Cho, B. C., & Shim, H. S. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.004 · Cited by 67
Sherafatian, M., & Arjmand, F. (2019) · Oncology Letters · doi:10.3892/ol.2019.10462 · Cited by 82
Riess, J. W., Frankel, P. H., Shackelford, D. B., Dunphy, M. P., Badawi, R. D., Nardo, L., Cherry, S. R., Lanza, I. R., Reid, J. M., Gonsalves, W. I., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.006 · Cited by 63
The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis
Liu, P., Luo, G., Dodson, M. B., Schmidlin, C. J., Wei, Y., Kerimoğlu, B., Ooi, A., Chapman, E., Garcia, J. G. N., & Zhang, D. D. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101766 · Cited by 69
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 84
Zhang, S., Balbo, S., Wang, M., & Hecht, S. S. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100321y · Cited by 63
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A.-C., Leong, S., Diamond, J. R., & Eckhardt, S. G. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 61
Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer
Brooks, Y., Ostano, P., Jo, S. H., Dai, J., Getsios, S., Dziunycz, P., Hofbauer, G. F. L., Cerveny, K. L., Chiorino, G., Lefort, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72718 · Cited by 71
Tani, T., Yasuda, H., Hamamoto, J., Kuroda, A., Arai, D., Ishioka, K., Ohgino, K., Miyawaki, M., Kawada, I., Naoki, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0084 · Cited by 69
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer
Terai, H., Tan, L., Beauchamp, E. M., Hatcher, J. M., Liu, Q., Meyerson, M. M., Gray, N. S., & Hammerman, P. S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00655 · Cited by 67
Ding, X., Zhang, Z., Jiang, T., Li, X., Zhao, C., Su, B., & Zhou, C. (2017) · Cancer Medicine · doi:10.1002/cam4.1014 · Cited by 67
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.